

DOENÇAS CARDIOVASCULARES x PIOGLITAZONE

"pioglitazone "[Substance Name] AND "Cardiovascular Diseases"[Mesh]

PUBMED SEM FILTRO - TOTAL = 287

PUBMED COM FILTRO = 66

"pioglitazone "[Substance Name] AND "Cardiovascular Diseases"[Mesh]

Limits: **Clinical Trial, Meta-Analysis, Practice Guideline, Randomized Controlled Trial**

PUBMED SYSTEMATIC REVIEW = 10

"pioglitazone "[Substance Name] AND "Cardiovascular Diseases"[Mesh]

Limits: **Systematic Reviews**

ESTRATÉGIA PARA REVISÃO SISTEMÁTICA

PIOGLITAZONE

(pioglitazone [Substance Name]) OR (5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione) OR (Actos) OR (Eli Lilly brand of pioglitazone hydrochloride) OR (Takeda brand of pioglitazone hydrochloride) OR (AD 4833) OR (AD-4833) OR (pioglitazone hydrochloride) OR (U 72107A) OR (U-72107A) OR (U72,107A)

AND

DOENÇAS CARDIOVASCULARES

("Cardiovascular Diseases"[Mesh]) OR (Cardiovascular Disease) OR (Disease, Cardiovascular) OR (Diseases, Cardiovascular)

AND

FILTRO PARA ESTRATEGIA

(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT humans [mh]))

RESULTADO PUBMED ESTRATEGIA PARA REVISÃO 183 ARTIGOS

COCHRANE LIBRARY

(pioglitazone:ti) - 18 encontrado(s)

- Revisões Sistemáticas da Cochrane (2)

- Revisões completas (2)

- Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome
- Pioglitazone for type 2 diabetes mellitus

- Protocolos (0 de)

Resumos de revisões sistemáticas com qualidade avaliada (4)

- Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation (Provisional record)
- Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis (Structured abstract)
- Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents (Provisional record)
- The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review (Structured abstract)

Registro Cochrane de Ensaios Controlados (CENTRAL/CCTR) (0 de)

Base de Dados Cochrane de Revisões de Metodologia (0)

Registro Cochrane de Metodologia (0 de)

Sobre a Colaboração Cochrane (0)

Resumos do INAHTA e de outras agências de Avaliação de Tecnologias em Saúde (5)

Resumos do INAHTA e de outras agências de Avaliação de Tecnologias em Saúde (5)

- Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis (Structured abstract)
- Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents (Structured abstract)
- The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review (Structured abstract)
- Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation (Structured abstract)
- Guidance on the use of pioglitazone for type 2 diabetes mellitus (Structured abstract)

Avaliações Econômicas da NHS (7)

- Avaliações econômicas revisadas (3)
 - Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective (Provisional record)
 - Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial (Structured abstract)
 - Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis (Provisional record)
- Outros estudos econômicos (4)
 - Economic benefits of pioglitazone for treating patients with Type 2 diabetes (Brief record)
 - The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review (Brief record)
 - Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population (Provisional record)
 - Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis (Provisional record)

LILACS